News / Taiwan / cnyes
Allgenesis Biotherapeutics August Revenue Climbs 157% YoY
Health Technology · Biotechnology · cnyes · 2026-09-09
6885
Biotech firm Allgenesis (6885) reported a 157.11% year-over-year revenue jump for August 2026, with cumulative growth exceeding 248% for the year.
What Happened
Revenue Performance: Allgenesis Biotherapeutics (6885) announced August 2026 revenue of NT$1.1 million, a 157.11% year-over-year increase and a 31.47% monthly improvement.
Year-to-Date Results: Cumulative revenue for the first eight months of 2026 reached NT$8.73 million, representing a significant cumulative year-over-year growth of 248.26%.
Stock Market Performance: The stock price reached NT$26.65, rising 8.33% over the last five days and outperforming the biotech sector index, which declined by 1.57%.
Company Profile: Allgenesis operates in the biotechnology industry, with a primary focus on the development of new pharmaceutical drugs.